Breaking News

DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge

Plans are to develop cell products and services for drug discovery and the study of lung diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DefiniGEN Ltd., a provider of stem cell life science products and services, has strengthened its IP portfolio with a licence for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimized cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis. The technology, licensed to DefiniGEN by Cambridge Enterprise, the commercialization arm of the University of Cambridge use...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters